PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3831

  1. 692 Posts.
    lightbulb Created with Sketch. 130
    My interpretation is more that "Delays in doing deals have been pitched as maximising the long term value of the asset."
    It makes sense to me - short term pain for greater long term gain.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.